NovaBridge Biosciences
Last updated September 27, 2026
Organization details
- Legal name
- NovaBridge Biosciences
- Ownership
- Public
- Status
- Active
- Headquarters country
- China
- Ticker symbol
- NBP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001778016
Board of directors
-
Chun Kwok Alan Au · DirectorSince 2026
-
Conor Chia-hung Yang · DirectorSince 2026
-
Emmett Cunningham · DirectorSince 2026
-
Ian Ying Woo · DirectorSince 2026
-
Robert A. Lenz · DirectorSince 2026
-
Sean Wuxiong Cao · Director · Chief Bus. Development OfficerSince 2026
-
Srishti Gupta · Director · Chief Executive OfficerSince 2026
-
Wei Fu · DirectorSince 2026
-
Xi-Yong Fu · Director · See RemarksSince 2026
-
Xin Liu · DirectorSince 2026
Chief executives
Srishti Gupta
· Chief Executive Officer
Since July 2026
Board connections
3 of this board's directors also sit on 4 other boards.
- via Conor Chia-hung Yang
- via Srishti Gupta
- via Robert A. Lenz
- via Conor Chia-hung Yang
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $577,300
- 1 purchase by 1 insider
- Sold, last 12 months
- $65,948
- 4 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 6, 2026 | Xu Cong Claire Officer (SVP, Clinical Development) | Open-market sale | −4,485 | $0.89 | $3,992 |
| Jul 4, 2026 | Xu Cong Claire Officer (SVP, Clinical Development) | Option exercise | +12,432 | — | — |
| Jun 18, 2026 | Dennis Phillip Andrew Officer (Chief Medical Officer) | Open-market sale | −8,494 | $0.66 | $5,606 |
| Jun 17, 2026 | Dennis Phillip Andrew Officer (Chief Medical Officer) | Option exercise | +23,695 | — | — |
| Jun 1, 2026 | Xu Cong Claire Officer (SVP, Clinical Development) | Open-market sale | −3,494 | $3.94 | $13,766 |
| May 30, 2026 | Xu Cong Claire Officer (SVP, Clinical Development) | Option exercise | +9,382 | — | — |
| May 14, 2026 | Sean Wuxiong Cao Director, Officer (See Remarks) | Open-market sale | −21,399 | $1.99 | $42,584 |
| Apr 24, 2026 | Hagler Mark Arnold Officer (See Remarks) | Open-market purchase | +230,000 | $2.51 | $577,300 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.